What patient education is needed for a patient to decide between stimulant (e.g., methylphenidate, amphetamine) and non‑stimulant (e.g., atomoxetine, guanfacine, clonidine) ADHD medications?

Patient Education for Choosing Between Stimulant and Non-Stimulant ADHD Medications

Patients should understand that stimulants are generally more effective (with effect sizes around 1.0 versus 0.7-0.8 for non-stimulants) and work within hours, but non-stimulants may be preferred or necessary based on specific comorbidities, substance use concerns, or when stimulants cause intolerable side effects. 1

Core Efficacy Differences

Stimulants (methylphenidate, amphetamines):

• Larger effect on ADHD symptoms - approximately 40% stronger than non-stimulants 1
• Rapid onset - effects visible within hours of first dose 1
• Work throughout the day but may wear off in afternoon/evening, potentially causing symptom rebound 1
• Multiple formulations available (short-acting, various long-acting options) 1

Non-stimulants (atomoxetine, guanfacine, clonidine):

• Delayed onset - atomoxetine takes 6-12 weeks, guanfacine/clonidine take 2-4 weeks to reach full effect 1
• "Around-the-clock" coverage - continuous symptom control without wearing off 1
• Smaller but still meaningful improvement in ADHD symptoms 1

Side Effect Profiles to Discuss

Stimulants:

• Appetite suppression and potential growth effects (1-2 cm reduction in height) 1, 2
• Sleep disturbances 1, 3
• Increased heart rate and blood pressure (mild, 1-4 mmHg) 1, 2
• Headaches, abdominal pain 3, 2
• Controlled substance status - requires special prescriptions, potential for diversion 1

Non-stimulants:

Atomoxetine:

• Initial stomach upset, headache 1
• Less appetite suppression than stimulants, fewer growth concerns 1
• FDA black box warning for suicidal ideation (rare, <0.4%) - requires monitoring 1, 4
• Not a controlled substance 1

Guanfacine/Clonidine:

• Somnolence/fatigue (common, especially initially) - best taken at bedtime 1
• Dry mouth, irritability 1
• Lowered blood pressure and heart rate 1
• Cannot stop abruptly - must taper to avoid rebound hypertension 2

When Non-Stimulants Should Be First-Line

Non-stimulants are preferred as initial treatment when patients have: 1

1. Active substance use disorder - stimulants pose diversion/abuse risk
2. Tic disorder or Tourette's syndrome - atomoxetine doesn't worsen tics; guanfacine may help
3. Significant sleep problems - guanfacine/clonidine can improve sleep
4. Disruptive behavior disorders - non-stimulants may be more effective
5. Anxiety disorders - atomoxetine may help comorbid anxiety
6. Strong family preference to avoid controlled substances

Timing and Practical Considerations

Stimulants:

• Need to decide on dosing schedule (once daily long-acting vs. multiple doses)
• May need afternoon dose for homework/activities 1
• Effects can be adjusted quickly (within days to weeks) 5
• Requires monitoring height, weight, blood pressure, pulse 1

Non-stimulants:

• Require patience - must wait weeks to months for full benefit 1
• Single daily dosing typically sufficient 1
• Atomoxetine can be split into morning/evening doses or given at bedtime to reduce side effects 1
• Requires monitoring blood pressure, pulse, and for atomoxetine, suicidal thoughts 1

Combination Therapy Option

If stimulants work but cause problematic side effects (sleep problems, elevated blood pressure), adding guanfacine or clonidine can:

• Reduce stimulant side effects 1
• Provide additional ADHD symptom control 1
• Both are FDA-approved for this augmentation strategy 1

Critical Monitoring Parameters

Before starting any medication, obtain:

• Personal and family cardiac history (sudden death, arrhythmias, structural heart disease) 2, 6
• Baseline height, weight, blood pressure, pulse 1
• For atomoxetine: baseline mood/suicidal ideation assessment 4

Common pitfall: Families discontinuing non-stimulants prematurely (within 2-4 weeks) before therapeutic effects emerge. Emphasize the delayed onset and need for patience 1.